New Drug ApprovalTeva Wins FDA Approval for WELTRUZA in Schizophrenia Teva Wins FDA Approval for WELTRUZA in Schizophrenia Read Post »
Clinical TrialsAlumis Reports Highest PASI 100 Response With Envudeucitinib Among Oral Pso... Alumis Reports Highest PASI 100 Response With Envudeucitinib Among Oral Pso... Read Post »
Clinical TrialsBMS Reports 51% Lower Progression Risk With ZENBEXUS BMS Reports 51% Lower Progression Risk With ZENBEXUS Read Post »
Health TidingsLife Bio Reports Preliminary Visual Field Improvements for ER-100 Life Bio Reports Preliminary Visual Field Improvements for ER-100 Read Post »
Clinical TrialsInnovent Reports TEPEZZA-Consistent Proptosis Reduction With SYCUME in Inac... Innovent Reports TEPEZZA-Consistent Proptosis Reduction With SYCUME in Inac... Read Post »
Health Tidings Mergers & AcquisitionsViatris to Acquire Pacira for $1.65 Billion Viatris to Acquire Pacira for $1.65 Billion Read Post »
Clinical TrialsPharvaris Reports Positive Results for Oral Deucrictibant in HAE Trial Pharvaris Reports Positive Results for Oral Deucrictibant in HAE Trial Read Post »
Clinical TrialsEndeavor’s Taladegib Improves Lung Function in Phase 2b IPF Trial Endeavor’s Taladegib Improves Lung Function in Phase 2b IPF Trial Read Post »
Clinical TrialsTopical Sildenafil Shows 187-Fold Lower Systemic Peak Than Oral Dose in Dar... Topical Sildenafil Shows 187-Fold Lower Systemic Peak Than Oral Dose in Dar... Read Post »
Health TidingsBiofrontera Submits sNDA to Expand Ameluz® PDT for Actinic Keratoses Beyon... Biofrontera Submits sNDA to Expand Ameluz® PDT for Actinic Keratoses Beyon... Read Post »
Health TidingsFDA Grants Orphan Drug Designation to vTv’ HPPD for Sickle Cell Disease FDA Grants Orphan Drug Designation to vTv’ HPPD for Sickle Cell Disease Read Post »
Health TidingsCullinan Advances CLN-049 Into Pivotal Phase 2 Study in Relapsed/Refractory... Cullinan Advances CLN-049 Into Pivotal Phase 2 Study in Relapsed/Refractory... Read Post »
Clinical TrialsCandel Reports 24.5-Month Median Overall Survival with Aglatimagene Besaden... Candel Reports 24.5-Month Median Overall Survival with Aglatimagene Besaden... Read Post »
Health TidingsFDA Fast Track Advances Development of PSV359 in FAP-Positive SFTs FDA Fast Track Advances Development of PSV359 in FAP-Positive SFTs Read Post »
Clinical TrialsForte-Acquired FB102 Delivers Positive Phase 2 Results in Celiac Disease Forte-Acquired FB102 Delivers Positive Phase 2 Results in Celiac Disease Read Post »
Clinical Trialsargenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... argenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... Read Post »
Health TidingsMHRA Approves Catumaxomab for Cancer-Related Abdominal Fluid Build-Up MHRA Approves Catumaxomab for Cancer-Related Abdominal Fluid Build-Up Read Post »
Health TidingsNewron Evenamide Faces FDA Clinical Hold in ENIGMA-TRS 2 Trial Newron Evenamide Faces FDA Clinical Hold in ENIGMA-TRS 2 Trial Read Post »
Drugs Safety AlertUK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review UK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review Read Post »
Health TidingsAtsena’s ATSN-201 Shows Microperimetry and Visual Gains in X-Linked Retin... Atsena’s ATSN-201 Shows Microperimetry and Visual Gains in X-Linked Retin... Read Post »
New Drug ApprovalFDA Approves Rhapsido as First Treatment for Symptomatic Dermographism FDA Approves Rhapsido as First Treatment for Symptomatic Dermographism Read Post »
New Drug ApprovalFDA Approves TUKYSA as First-Line Maintenance in Breast Cancer FDA Approves TUKYSA as First-Line Maintenance in Breast Cancer Read Post »
Clinical TrialsZealand’s Petrelintide Shows 9.2% Weight Loss and HbA1c Benefit in ZU... Zealand’s Petrelintide Shows 9.2% Weight Loss and HbA1c Benefit in ZU... Read Post »
Health TidingsPositive Phase 3 ARISE Results Support Potential NDA Path for Cerevance’s... Positive Phase 3 ARISE Results Support Potential NDA Path for Cerevance’s... Read Post »
Health TidingsRuvonoflast Plus Semaglutide Shows Greater HsCRP Reduction Ruvonoflast Plus Semaglutide Shows Greater HsCRP Reduction Read Post »
Health TidingsSurVaxM Shows Significant Survival Benefit in Patients Aged 65 and Under Wi... SurVaxM Shows Significant Survival Benefit in Patients Aged 65 and Under Wi... Read Post »
Clinical TrialsRezdiffra Shows Consistent Response Across MASH Genetic Risk Groups Rezdiffra Shows Consistent Response Across MASH Genetic Risk Groups Read Post »
Health TidingsAbbVie’s Temab-A Receives Two Breakthrough Therapy Designations for CRC a... AbbVie’s Temab-A Receives Two Breakthrough Therapy Designations for CRC a... Read Post »
Health TidingsMatchpoint Raises $150 Million to Advance Oral T-Cell Modulator MPT-062 Matchpoint Raises $150 Million to Advance Oral T-Cell Modulator MPT-062 Read Post »
Clinical TrialsPulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 ... PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 ... Read Post »
Health TidingsArrowhead Granted FDA STAR Entry for Plozasiran sNDA in sHTG Arrowhead Granted FDA STAR Entry for Plozasiran sNDA in sHTG Read Post »
Health TidingsFDA Supports Proposed Clinical Study of Bausch + Lomb’s BL1243 for Dry AM... FDA Supports Proposed Clinical Study of Bausch + Lomb’s BL1243 for Dry AM... Read Post »
Clinical TrialsMUVON Reports Sustained Benefit at 12 Months in SUI Study MUVON Reports Sustained Benefit at 12 Months in SUI Study Read Post »
Health TidingsKymaThera Raises $80M to Advance K-1728 PI3Kα Inhibitor KymaThera Raises $80M to Advance K-1728 PI3Kα Inhibitor Read Post »
Clinical TrialsEpicrispr’s EPI-321 Shows Increased Muscle Volume and Strength at Six Mon... Epicrispr’s EPI-321 Shows Increased Muscle Volume and Strength at Six Mon... Read Post »
Clinical TrialsViiV Healthcare’s Cabenuva Shows Superior Viral Suppression in CROWN Stud... ViiV Healthcare’s Cabenuva Shows Superior Viral Suppression in CROWN Stud... Read Post »
Health TidingsEnliven Reaches FDA Alignment on Phase 3 ENABLE-2 Trial of Relcobatinib in ... Enliven Reaches FDA Alignment on Phase 3 ENABLE-2 Trial of Relcobatinib in ... Read Post »
Clinical TrialsArriVent’s Firmonertinib Fails Primary PFS Endpoint Despite Higher ORR in... ArriVent’s Firmonertinib Fails Primary PFS Endpoint Despite Higher ORR in... Read Post »
Health TidingsOkogen Gets CDSCO Authorization to Advance Treyegen for Acute Infectious Co... Okogen Gets CDSCO Authorization to Advance Treyegen for Acute Infectious Co... Read Post »
Health TidingsForward Reports Positive Phase 1 Data for FT2109, Advances to Phase 2 in Rh... Forward Reports Positive Phase 1 Data for FT2109, Advances to Phase 2 in Rh... Read Post »
GenericsLupin Launches Formoflo-G MDI in India for COPD Triple Therapy Lupin Launches Formoflo-G MDI in India for COPD Triple Therapy Read Post »
Health TidingsBridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infi... BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infi... Read Post »
Health TidingsViking Initiates VK2735 Oral Maintenance Trial in Patients with Obesity Viking Initiates VK2735 Oral Maintenance Trial in Patients with Obesity Read Post »
Clinical TrialsKairos Reports Significant PFS Improvement With ENV-105 in mCRPC Kairos Reports Significant PFS Improvement With ENV-105 in mCRPC Read Post »
Health TidingsPreclinical Biotech Company RougeTx Launches with $58 Million Series A to A... Preclinical Biotech Company RougeTx Launches with $58 Million Series A to A... Read Post »
Clinical TrialsLundbeck Reports Increased Good ON-Time and Reduced Dyskinesia in Phase Ib ... Lundbeck Reports Increased Good ON-Time and Reduced Dyskinesia in Phase Ib ... Read Post »
Health Tidings Mergers & AcquisitionsShionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Shionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Read Post »
Medical DevicesClick’s Motivista Receives FDA Clearance for Negative Symptoms of Schizop... Click’s Motivista Receives FDA Clearance for Negative Symptoms of Schizop... Read Post »
Clinical TrialsEpcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Epcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Read Post »
Health Tidings Mergers & AcquisitionsAlector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Alector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Read Post »
